SCHEMBL147599

SCHEMBL147599

O=C(Cl)c1cccc(Br)c1F

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
ALOX15 P16050 1/20 0.52
CES2 O00748 2/20 0.42
CES1 P23141 2/20 0.42
BCHE P06276 1/20 0.42
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
NPC1 O15118 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAOB P27338 2/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
PRNP P04156 1/20 0.37
CTSL P07711 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALB P02768 1/20 0.35
MIF P14174 1/20 0.35
LCLAT1 Q6UWP7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31184721 1.00 ALDH1A1 (0.52) ALDH1A1ALOX15CES2CES1BCHE
SCHEMBL19185970 0.84 ALDH1A1 (0.62) ALDH1A1ALOX15CES2CES1BCHE
SCHEMBL29570698 0.81 PRNP (0.50) ALDH1A1ALOX15CES2CES1BCHE
SCHEMBL9217406 0.81 CES2 (0.43) ALDH1A1ALOX15CES2CES1BCHE
SCHEMBL18640539 0.81 ALDH1A1 (0.43) ALDH1A1ALOX15CES2CES1BCHE
SCHEMBL11135091 0.81 CES2 (0.43) ALDH1A1ALOX15CES2CES1BCHE
SCHEMBL146386 0.81 PRNP (0.50) ALDH1A1ALOX15CES2CES1BCHE
SCHEMBL145431 0.79 DGAT1 (0.46) ALDH1A1CES2CES1BCHELMNA
SCHEMBL1849109 0.79 CES2 (0.42) ALDH1A1CES2CES1BCHELMNA
SCHEMBL20560192 0.79 CTSL (0.42) ALDH1A1ALOX15CES2CES1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109503416-A A kind of miscellaneous Shandong amine intermediate synthetic method of grace 常州智超化学有限公司 2019-03-22 CN claimed
US-12622909-B2 Allosteric EGFR inhibitors and methods of use thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-12 US disclosed
US-20250326777-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) 2025-10-23 US disclosed
EP-4605374-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF Hepaitech (Beijing) Biopharma Technology Co., Ltd. (CN) 2025-08-27 EP disclosed
CN-120129676-A Compounds, compositions, and methods thereof 海湃泰克(北京)生物医药科技有限公司 2025-06-10 CN disclosed
EP-4537902-A2 TRICYCLIC ASK1 INHIBITORS Terns, Inc. (US) 2025-04-16 EP disclosed
EP-3773577-B1 TRICYCLIC ASK1 INHIBITORS TERNS INC (US) 2024-11-20 EP disclosed
CN-114206342-B Allosteric EGFR inhibitors and methods of use thereof 达纳-法伯癌症研究所股份有限公司 2024-10-22 CN disclosed
CN-118480001-A C-Kit (V559D)/PDGFR beta double-target allosteric inhibitor and preparation method, pharmaceutical composition and application thereof 贵州省天然产物研究中心 2024-08-13 CN disclosed
WO-2024083210-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) 2024-04-25 WO disclosed
US-20100273773-A1 DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 US disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed
WO-2009158369-A1 SYNTHESIS AND USE OF HETEROCYCLIC ANTIBACTERIAL AGENTS SCHERING CORPORATION (US) 2009-12-30 WO disclosed
WO-2009071631-A2 DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2009-06-11 WO disclosed
CN-101389630-A Protein kinase inhibitors ABBOTT LAB (US) 2009-03-18 CN disclosed
EP-1954132-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2008-08-13 EP disclosed
WO-2007100758-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-09-07 WO disclosed
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622909-B2 Allosteric EGFR inhibitors and methods of use thereof EGFR, ERBB3, ERBB2 ALDH1A1 4245/4885ALOX15 4364/4885CES2 2480/4885
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 ALDH1A1 2482/4885ALOX15 2854/4885CES2 550/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 ALDH1A1 3832/4885ALOX15 4154/4885CES2 1202/4885
US-20100273773-A1 DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS TRPA1, TRPV1, TRPV2 ALDH1A1 655/4885ALOX15 83/4885CES2 2005/4885
US-20250326777-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF MRGPRX4, MRGPRX1, MRGPRX2 ALDH1A1 1047/4885ALOX15 1032/4885CES2 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.